Upexi Reports Fiscal Third Quarter 2024 Financial Results
Upexi (NASDAQ:UPXI) reported its financial results for the fiscal third quarter ending March 31, 2024. Revenues decreased by 34% to $14.4 million, primarily due to lower recommerce revenue and the discontinuation of electronic product sales on Amazon. Costs of revenue fell by 19% to $11.6 million, with gross profit decreasing by $1.7 million due to write-offs of obsolete inventory.
Sales and marketing expenses dropped by 32%, and general and administrative expenses decreased by 8%. Despite these reductions, the company reported a net loss of $4.1 million, up from $1.7 million the previous year, largely due to decreased sales and inventory write-offs. Subsequent to the quarter, Upexi continued restructuring, including a new lease agreement and the sale of a warehouse, aiming to ensure sufficient working capital for the next 12 months.
- Cost of revenue decreased by 19% to $11.6 million.
- Sales and marketing expenses decreased by 32%.
- General and administrative expenses decreased by 8%.
- Operating expenses decreased by 37%.
- New agreements to reduce future operating expenses.
- Estimated sufficient working capital to fund operations for the next 12 months.
- Revenues decreased by 34% to $14.4 million.
- Gross profit decreased due to $1.7 million in inventory write-offs.
- Net loss increased to $4.1 million from $1.7 million.
- Other expenses increased due to higher interest on debt.
Insights
Upexi's fiscal third-quarter financial results indicate significant downward trends, which should be viewed with caution by investors. Revenue decreased by 34% compared to the same period last year, primarily due to lower recommerce revenue and the strategic discontinuation of electronic product sales on Amazon channels. The decision to cease these sales is logical given the high rate of returns and low margins; however, it also highlights challenges in managing product lines effectively.
The cost of revenue also decreased by 19%, but the reduction in gross profit by approximately
On a positive note, sales and marketing expenses decreased by 32%, indicating that management is actively working to streamline operations and focus on more profitable sales channels. However, the overall financial health of Upexi appears compromised as they posted a net loss of
For retail investors, the restructuring efforts and strategic focus on profitability rather than growth are essential points to monitor. The company’s management is taking steps to reduce debt and improve the balance sheet, but these efforts need to translate into tangible financial improvements in the upcoming quarters. Investors should consider the short-term pains against potential long-term gains, especially with management's optimism about future profitability.
Upexi's current restructuring focuses on shifting their product strategy to more stable revenue streams, such as branded products and subscription services. The slight increase in branded product sales, particularly in pet care and children's toy products, shows potential areas of growth that are less reliant on volatile channels like Amazon.
The decision to cut back on sales of electronic products due to high return rates and low margins is a smart move, albeit a painful one in the short term. This pivot to more sustainable and less risky revenue streams can lead to a more predictable and stable business model, as long as the execution of this strategy is feasible and consistent.
Additionally, the decrease in sales and marketing expenses indicates that the company is refining its sales approach for long-term growth. However, the market remains skeptical, as evidenced by the net loss and operational challenges. The sale of the warehouse and a wholly-owned subsidiary is aimed at freeing up capital and reducing debt. For retail investors, the key takeaway is to monitor how effectively the company can transition to a more scalable and sustainable business model while maintaining financial discipline.
From an operational standpoint, Upexi is undergoing a significant restructuring aimed at improving efficiency and scalability. The reduction in general and administrative expenses by 8% and other operating expenses by 37% indicates a concerted effort to streamline operations and cut unnecessary costs.
The company's focus on consolidating facilities and reducing high-interest debt is a prudent move, especially given the current lending market conditions. However, the immediate increase in net loss to
For investors, the main concern is whether these operational changes will lead to sustainable profitability. The company needs to demonstrate that its restructuring efforts can generate consistent cash flow and reduce its dependency on volatile product lines.
TAMPA, FL / ACCESSWIRE / July 9, 2024 / Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a multi-faceted Amazon and Direct-to-Consumer ("DTC") brand owner and innovator in aggregation, today reported its financial results for the fiscal third quarter 2024 ending March 31, 2024.
Allan Marshall, CEO of Upexi, commented, "Our year-over-year quarterly financial results include management's decision to discontinue sales of certain products. Subsequent to the quarter, we made continued progress on our restructuring, which is estimated to provide us with sufficient working capital to fund our operations while reducing our debt to a minimal level. We anticipate the restructuring efforts to result in a leaner more scalable business with an improved balance sheet. Current market conditions and the lack of a healthy lending market has made these difficult decisions necessary. The alternative of a highly dilutive equity raise was a non-starter for management and hard decisions were made to give shareholders the best opportunity for future success. This reset will allow management to focus on opportunities for profitable growth without the debt issue hampering success. We will provide our shareholders with an updated outlook on our operations and detailed financial goals as we complete the final stages as quickly as possible."
Financial Results for the Three Months Ended March 31, 2024:
Revenues decreased
Cost of revenue decreased
Sales and marketing expenses decreased
General and administrative expenses decreased
Other operating expenses decreased
During the three months ended March 31, 2024, the Company had other expense of
The Company had a net loss of
Subsequent Events:
Subsequent to March 31, 2024, the Company entered into a new lease agreement reducing annualized operating expenses, an agreement to sell its warehouse for approximately
About Upexi, Inc.:
Upexi is a multi-faceted brand owner with established brands in the health, wellness, pet, beauty, and other growing markets. We operate in emerging industries with high growth trends and look to drive organic growth of our current brands. We focus on direct to consumer and Amazon brands that are scalable and have anticipated, high industry growth trends. Our goal is to continue to accumulate consumer data and build out a significant customer database across all industries we sell into. The growth of our current database has been key to the year-over-year gains in sales and profits. To drive additional growth, we have and will continue to acquire profitable Amazon and eCommerce businesses that can scale quickly and reduce costs through corporate synergies.
FORWARD LOOKING STATEMENTS:
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations, or intentions regarding the future. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with business strategy, potential acquisitions, revenue guidance, product development, integration, and synergies of acquiring companies and personnel. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward- looking statements. Although we believe that the beliefs, plans, expectations, and intentions contained in this press release are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
Company Contact
Andrew Norstrud, Chief Financial Officer
Email: andrew.norstrud@upexi.com
Phone: (702) 332-5591
Investor Relations Contact
KCSA Strategic Communications
Valter Pinto, Managing Director
Email: Upexi@KCSA.com
Phone: (212) 896-1254
UPEXI, INC.
CONDENSED CONSOLDIATED BALANCE SHEETS (UNAUDITED)
| March 31, |
|
| June 30, |
| |||
| 2024 |
|
| 2023 |
| |||
|
|
|
|
|
| |||
ASSETS |
|
|
|
|
|
| ||
Current assets |
|
|
|
|
|
| ||
Cash |
| $ | 498,287 |
|
| $ | 4,492,291 |
|
Accounts receivable |
|
| 4,707,128 |
|
|
| 6,963,915 |
|
Inventory |
|
| 8,801,901 |
|
|
| 9,267,892 |
|
Due from Bloomios |
|
| - |
|
|
| 845,443 |
|
Prepaid expenses and other receivables |
|
| 720,582 |
|
|
| 1,283,617 |
|
Current assets of discontinued operations |
|
| 2,111,952 |
|
|
| 2,602,556 |
|
Total current assets |
|
| 16,839,850 |
|
|
| 25,455,714 |
|
|
|
|
|
|
|
|
| |
Property and equipment, net |
|
| 7,520,005 |
|
|
| 7,442,623 |
|
Intangible assets, net |
|
| 9,469,923 |
|
|
| 12,588,124 |
|
Goodwill |
|
| 10,847,791 |
|
|
| 9,290,501 |
|
Deferred tax asset |
|
| 8,273,049 |
|
|
| 5,604,056 |
|
Other assets |
|
| 368,004 |
|
|
| 76,728 |
|
Assets held for sale |
|
| 1,675,112 |
|
|
| 2,984,868 |
|
Right-of-use asset |
|
| 1,513,693 |
|
|
| 410,453 |
|
Total other assets |
|
| 39,667,577 |
|
|
| 38,397,353 |
|
|
|
|
|
|
|
|
| |
Total assets |
| $ | 56,507,427 |
|
| $ | 63,853,067 |
|
|
|
|
|
|
|
|
| |
LIABILITIES AND STOCKHOLDERS' EQUITY |
|
|
|
|
|
|
|
|
Current liabilities |
|
|
|
|
|
|
|
|
Accounts payable |
| $ | 2,124,024 |
|
| $ | 3,930,540 |
|
Accrued compensation |
|
| 841,064 |
|
|
| 533,842 |
|
Deferred revenue |
|
| 111,519 |
|
|
| - |
|
Accrued liabilities |
|
| 2,551,149 |
|
|
| 3,350,541 |
|
Acquisition payable |
|
| 300,000 |
|
|
| - |
|
Current portion of notes payable |
|
| 5,473,136 |
|
|
| 1,302,021 |
|
Current portion of convertible notes payable |
|
| - |
|
|
| 1,254,167 |
|
Current portion of acquisition note payable |
|
| 8,048,562 |
|
|
| 5,656,620 |
|
Current portion of related party note payable |
|
| - |
|
|
| 1,429,356 |
|
Line of Credit |
|
| 3,938,772 |
|
|
| 882,845 |
|
Current portion of operating lease payable |
|
| 803,558 |
|
|
| 419,443 |
|
Current liabilities of discontinued operations |
|
| - |
|
|
| 975,310 |
|
Total current liabilities |
|
| 24,191,784 |
|
|
| 19,734,685 |
|
|
|
|
|
|
|
|
| |
Operating lease payable, net of current portion |
|
| 1,055,301 |
|
|
| 34,684 |
|
Related party note payable |
|
| 1,479,815 |
|
|
| - |
|
Convertible notes payable |
|
| 1,650,000 |
|
|
| 895,833 |
|
Acquisition notes payable, net of current |
|
| 2,929,393 |
|
|
| 7,605,085 |
|
Notes payable, net of current portion |
|
| 3,144,327 |
|
|
| 7,746,157 |
|
Total long-term liabilities |
|
| 10,258,836 |
|
|
| 16,281,759 |
|
|
|
|
|
|
|
|
| |
Commitments and contingencies |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
Stockholders' equity |
|
|
|
|
|
|
|
|
Preferred stock, |
|
| 500 |
|
|
| 500 |
|
Common stock, |
|
| 20,909 |
|
|
| 20,216 |
|
Additional paid in capital |
|
| 53,149,492 |
|
|
| 51,522,229 |
|
Accumulated deficit |
|
| (31,114,094 | ) |
|
| (23,201,175 | ) |
Total stockholders' equity attributable to Upexi, Inc. |
|
| 22,056,807 |
|
|
| 28,341,770 |
|
Non-controlling interest in subsidiary |
|
|
|
|
|
| (505,147 | ) |
Total stockholders' equity |
|
| 22,056,807 |
|
|
| 27,836,623 |
|
|
|
|
|
|
|
|
| |
Total liabilities and stockholders' equity |
| $ | 56,507,427 |
|
| $ | 63,853,067 |
|
UPEXI, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
| Three Month's Ended March 31, |
| ||||||
| 2024 |
|
| 2023 |
| |||
|
|
|
|
|
| |||
Revenue |
|
|
|
|
|
| ||
Revenue |
| $ | 14,444,957 |
|
| $ | 21,883,445 |
|
|
|
|
|
|
|
|
| |
Cost of Revenue |
|
| 11,561,834 |
|
|
| 14,305,698 |
|
|
|
|
|
|
|
|
| |
Gross profit |
|
| 2,883,123 |
|
|
| 7,577,747 |
|
|
|
|
|
|
|
|
| |
Operating expenses |
|
|
|
|
|
|
|
|
Sales and marketing |
|
| 1,547,161 |
|
|
| 2,258,937 |
|
Distribution costs |
|
| 2,291,945 |
|
|
| 2,352,684 |
|
General and administrative expenses |
|
| 2,399,387 |
|
|
| 2,602,312 |
|
Share-based compensation |
|
| 212,758 |
|
|
| 1,146,299 |
|
Amortization of acquired intangible assets |
|
| 1,062,734 |
|
|
| 1,124,500 |
|
Depreciation |
|
| 306,185 |
|
|
| 225,879 |
|
|
| 7,820,170 |
|
|
| 9,710,611 |
| |
|
|
|
|
|
|
|
| |
Loss from operations |
|
| (4,937,047 | ) |
|
| (2,132,864 | ) |
|
|
|
|
|
|
|
| |
Other income (expense), net |
|
|
|
|
|
|
|
|
Change in derivative liability |
|
| - |
|
|
| - |
|
Interest (expense) income, net |
|
| 661,878 |
|
|
| 152,360 |
|
|
|
|
|
|
|
|
| |
Other income (expense), net |
|
| 661,878 |
|
|
| 152,360 |
|
|
|
|
|
|
|
|
| |
Income (loss) on operations before income tax |
|
| (5,598,925 | ) |
|
| (1,980,504 | ) |
Gain on sale of Infusionz and select assets |
|
| - |
|
|
| - |
|
Gain (loss) from the sale of Interactive Offers |
|
| (103,263 | ) |
|
| - |
|
Lease settlement, California facility |
|
| - |
|
|
| - |
|
Lease impairment, Delray Beach facility |
|
| - |
|
|
| - |
|
Income tax benefit (expense) |
|
| 1,501,595 |
|
|
| 496,880 |
|
|
|
|
|
|
|
|
| |
Net income (loss) from continuing operations |
|
| (4,200,593 | ) |
|
| (1,483,624 | ) |
|
|
|
|
|
|
|
| |
(Loss) income from discontinued operations |
|
| 81,981 |
|
|
| (287,119 | ) |
|
|
|
|
|
|
|
| |
Net loss attributable to non-controlling interest |
|
| - |
|
|
| 124,804 |
|
|
|
|
|
|
|
|
| |
Net income (loss) attributable to Upexi, Inc. |
| $ | (4,118,612 | ) |
| $ | (1,645,939 | ) |
|
|
|
|
|
|
|
| |
Basic income (loss) per share: |
|
|
|
|
|
|
|
|
Income (loss) per share from continuing operations |
| $ | (0.20 | ) |
| $ | (0.08 | ) |
(Loss) income per share from discontinued operations |
| $ | 0.00 |
|
| $ | (0.02 | ) |
Total income (loss) per share |
| $ | (0.20 | ) |
| $ | (0.09 | ) |
|
|
|
|
|
|
|
| |
Diluted income (loss) per share: |
|
|
|
|
|
|
|
|
Income (loss) per share from continuing operations |
| $ | (0.20 | ) |
| $ | (0.08 | ) |
(Loss) income per share from discontinued operations |
| $ | 0.00 |
|
| $ | (0.02 | ) |
Total income (loss) per share |
| $ | (0.20 | ) |
| $ | (0.09 | ) |
|
|
|
|
|
|
|
| |
Basic weighted average shares outstanding |
|
| 20,723,542 |
|
|
| 18,015,837 |
|
Fully diluted weighted average shares outstanding |
|
| 20,723,542 |
|
|
| 18,015,837 |
|
UPEXI, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
| Nine Month's Ended March 31, |
| ||||||
| 2024 |
|
| 2023 |
| |||
Cash flows from operating activities |
|
|
|
|
|
| ||
Net (loss) income from operations |
| $ | (7,912,919.00 | ) |
| $ | (1,568,180.00 | ) |
|
|
|
|
|
|
|
| |
Adjustments to reconcile net income from continuing operations to net cash provided by operating activities: |
|
|
|
|
|
|
|
|
Depreciation and amortization |
|
| 4,089,722 |
|
|
| 3,359,050 |
|
Accrued interest on note receivable from Bloomios |
|
| - |
|
|
| (141,635 | ) |
Amortization of senior security original issue discount |
|
| - |
|
|
| (455,450 | ) |
Unreimbursed transition fees from Bloomios |
|
| - |
|
|
| (428,500 | ) |
Amortization of loan costs |
|
| 50,459 |
|
|
| - |
|
Amortization of consideration discount |
|
| 900,339 |
|
|
| - |
|
Non-cash consideration for sale of Infusionz and select assets, net |
|
| - |
|
|
| (7,564,363 | ) |
Inventory write-offs |
|
| 1,812,319 |
|
|
| 34,328 |
|
Gain on sale of interactive offers |
|
| (237,670 | ) |
|
| - |
|
Change in deferred tax asset |
|
| (2,668,993 | ) |
|
| (515,089 | ) |
Noncontrolling interest |
|
| - |
|
|
| (358,390 | ) |
Shares issued for finder fee |
|
| - |
|
|
| 1,770 |
|
Stock based compensation |
|
| 965,229 |
|
|
| 3,126,472 |
|
Changes in assets and liabilities, net of acquired amounts |
|
|
|
|
|
|
|
|
Accounts receivable |
|
| 2,413,987 |
|
|
| 2,175,850 |
|
Inventory |
|
| (255,500 | ) |
|
| 2,561,502 |
|
Prepaid expenses and other assets |
|
| 492,343 |
|
|
| 94,178 |
|
Operating lease payable |
|
| 301,492 |
|
|
| (22,830 | ) |
Accounts payable and accrued liabilities |
|
| (2,775,503 | ) |
|
| 1,744,961 |
|
Deferred revenue |
|
| (22,431 | ) |
|
| - |
|
Net cash provided by operating activities - Continuing Operations |
|
| (2,847,126 | ) |
|
| 2,043,674 |
|
Net cash provided by (used in) operating activities - Discontinued Operations |
|
| (187,280 | ) |
|
| 190,539 |
|
Net cash provided by operating activities |
|
| (3,034,406 | ) |
|
| 2,234,213 |
|
|
|
|
|
|
|
|
| |
Cash flows from investing activities |
|
|
|
|
|
|
|
|
Acquisition of Lucky Tail |
|
| - |
|
|
| (3,012,327 | ) |
Acquisition of VitaMedica, Inc., net of cash acquired |
|
| - |
|
|
| (500,000 | ) |
Acquisition of New England Technology, Inc. |
|
| - |
|
|
| (1,698,748 | ) |
Proceeds from the sale of Interactive Offers, net of liabilities paid |
|
| 940,000 |
|
|
| - |
|
Acquisition of patent rights for Tytan Tiles |
|
| (70,000 | ) |
|
| - |
|
Acquisition of Cygnet Online LLC, net of cash acquired |
|
| (500,000 | ) |
|
| (1,050,000 | ) |
Proceeds from the sale of Infusionz and selected assets |
|
| - |
|
|
| 5,173,610 |
|
Acquisition of property and equipment |
|
| (770,721 | ) |
|
| (278,683 | ) |
Net cash provided by (used in) investing activities - Continuing Operations |
|
| (400,721 | ) |
|
| (1,366,148 | ) |
Net cash (used in) provided by investing activities - Discontinued Operations |
|
| - |
|
|
| - |
|
Net cash provided by (used in) investing activities |
|
| (400,721 | ) |
|
| (1,366,148 | ) |
|
|
|
|
|
|
|
| |
Cash flows from financing activities |
|
|
|
|
|
|
|
|
Repayment of notes payable |
|
| (430,715 | ) |
|
| (470,168 | ) |
Repayment of the senior convertible notes payable |
|
| - |
|
|
| (6,307,775 | ) |
Proceeds (payments) on line of credit, net |
|
| 3,055,927 |
|
|
| (6,826,338 | ) |
Payment on acquisition notes payable |
|
| (3,184,089 | ) |
|
|
|
|
Repayment of SBA note payable |
|
|
|
|
|
| (254,804 | ) |
Proceeds from convertible note payable |
|
| - |
|
|
| 2,650,000 |
|
Proceeds on note payable on building |
|
| - |
|
|
| 3,000,000 |
|
Repayment on note payable on building |
|
|
|
|
|
| (97,744 | ) |
Proceeds on note payable, related party |
|
| - |
|
|
| 1,470,000 |
|
Net cash used in financing activities - Continuing Operations |
|
| (558,877 | ) |
|
| (6,836,829 | ) |
Net cash (used in) provided by financing activities - Discontinued Operations |
|
| - |
|
|
| - |
|
Net cash used in financing activities |
|
| (558,877 | ) |
|
| (6,836,829 | ) |
|
|
|
|
|
|
|
| |
Net decrease in cash - Continuing Operations |
|
| (3,806,724 | ) |
|
| (6,159,303 | ) |
Net (decrease) increase in cash - Discontinued Operations |
|
| (187,280 | ) |
|
| 190,539 |
|
|
|
|
|
|
|
|
| |
Cash, beginning of period |
|
| 4,492,291 |
|
|
| 7,149,806 |
|
Cash, end of period |
| $ | 498,287 |
|
| $ | 1,181,042 |
|
|
|
|
|
|
|
|
| |
Supplemental cash flow disclosures |
|
|
|
|
|
|
|
|
Interest paid |
| $ | 1,505,162 |
|
| $ | 326,918 |
|
Income tax paid |
| $ | - |
|
| $ | - |
|
Issuance of common stock for acquisition of Cygnet |
| $ | 162,727 |
|
| $ | - |
|
Issuance of debt for acquisition of Cygnet |
| $ | 300,000 |
|
| $ | - |
|
Bloomios non-cash payment of receivables, net |
| $ | 845,443 |
|
| $ | - |
|
Issuance of common stock for the repayment of convertible note payable |
| $ | 500,000 |
|
| $ | - |
|
Liabilities assumed from acquisition of E-Core |
| $ | - |
|
| $ | (7,712,168 | ) |
Issuance of stock for acquisition of E-Core |
| $ | - |
|
| $ | 6,000,000 |
|
Assets available for sale |
| $ | - |
|
| $ | 6,446,210 |
|
SOURCE: Upexi
View the original press release on accesswire.com
FAQ
What were Upexi's fiscal third-quarter 2024 revenues?
Why did Upexi's revenues decline in the fiscal third quarter of 2024?
What was Upexi's net loss for the fiscal third quarter of 2024?
How much did Upexi's sales and marketing expenses decrease in the fiscal third quarter of 2024?